BR112018074334A2 - uso de células tronco mesenquimais e partes das mesmas - Google Patents

uso de células tronco mesenquimais e partes das mesmas

Info

Publication number
BR112018074334A2
BR112018074334A2 BR112018074334-8A BR112018074334A BR112018074334A2 BR 112018074334 A2 BR112018074334 A2 BR 112018074334A2 BR 112018074334 A BR112018074334 A BR 112018074334A BR 112018074334 A2 BR112018074334 A2 BR 112018074334A2
Authority
BR
Brazil
Prior art keywords
stem cells
mesenchymal stem
parts
medicament
immunomodulatory particles
Prior art date
Application number
BR112018074334-8A
Other languages
English (en)
Inventor
J. Hoogduijn Martin
Original Assignee
Erasmus University Medical Center Rotterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasmus University Medical Center Rotterdam filed Critical Erasmus University Medical Center Rotterdam
Publication of BR112018074334A2 publication Critical patent/BR112018074334A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Abstract

a invenção refere-se às partículas imunomoduladoras de células tronco mesenquimais lisadas, compreendendo estruturas membranosas das ditas células tronco mesenquimais, e a seu uso como um medicamento. o dito medicamento preferivelmente é para o tratamento de doenças inflamatórias agudas e crônicas e de doenças auto-imunes. a invenção refere-se ainda a uma composição farmacêutica compreendendo as partículas imunomoduladoras e às células tronco mesenquimais inativadas ou partes das mesmas, para o uso como um medicamento.
BR112018074334-8A 2016-05-25 2017-05-26 uso de células tronco mesenquimais e partes das mesmas BR112018074334A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16171332 2016-05-25
EP16171332.6 2016-05-25
PCT/NL2017/050334 WO2017204639A1 (en) 2016-05-25 2017-05-26 Use of mesenchymal stem cells and parts thereof

Publications (1)

Publication Number Publication Date
BR112018074334A2 true BR112018074334A2 (pt) 2019-03-06

Family

ID=56081309

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074334-8A BR112018074334A2 (pt) 2016-05-25 2017-05-26 uso de células tronco mesenquimais e partes das mesmas

Country Status (9)

Country Link
US (1) US20190255115A1 (pt)
EP (1) EP3464564A1 (pt)
JP (1) JP2019516771A (pt)
CN (1) CN109715787A (pt)
AU (1) AU2017269053A1 (pt)
BR (1) BR112018074334A2 (pt)
CA (1) CA3025285A1 (pt)
IL (1) IL263265A (pt)
WO (1) WO2017204639A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102096150B1 (ko) 2018-01-05 2020-04-02 재단법인 아산사회복지재단 인터페론 감마로 전처리된 유도만능 줄기세포 유래 중간엽 줄기세포 및 이로부터 유래된 엑소좀을 포함하는 피부질환의 개선, 예방 또는 치료용 조성물
KR20210065963A (ko) 2018-09-17 2021-06-04 에라스무스 유니버시티 메디컬 센터 로테르담 아데노좀
JPWO2020184425A1 (pt) * 2019-03-08 2020-09-17
CN110777113B (zh) * 2019-09-10 2021-09-24 中山大学 一种用于日本血吸虫感染治疗的间质干细胞处理方法
CN111265549B (zh) * 2020-03-02 2022-03-01 苏州大学 表面pd-l1分子过表达的间充质干细胞膜包被的仿生纳米颗粒及其制备和应用
CN112921003B (zh) * 2021-02-02 2024-02-09 苏州大学 表达pd-l1分子的间充质干细胞来源外泌体及其制备方法与应用
WO2022221672A1 (en) * 2021-04-16 2022-10-20 Ossium Health, Inc. Interferon gamma-primed mesenchymal stromal cells as prophylaxis for graft versus host disease
CN117979969A (zh) * 2021-08-19 2024-05-03 康干细胞生物技术有限公司 利用钙依赖磷酸酶抑制剂和干细胞治疗免疫性疾病的方法
CN115177636A (zh) * 2022-07-18 2022-10-14 陕西科美致尚生物科技有限公司 一种用于治疗前列腺钙化的组合物及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20110403A1 (it) * 2011-07-28 2013-01-29 Ospedale Pediatrico Bambino Gesu Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori.
CN102936578B (zh) * 2012-11-12 2014-09-10 山东省齐鲁干细胞工程有限公司 一种增强间充质干细胞免疫抑制功能的方法

Also Published As

Publication number Publication date
CN109715787A (zh) 2019-05-03
WO2017204639A1 (en) 2017-11-30
EP3464564A1 (en) 2019-04-10
US20190255115A1 (en) 2019-08-22
IL263265A (en) 2018-12-31
CA3025285A1 (en) 2017-11-30
JP2019516771A (ja) 2019-06-20
AU2017269053A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
BR112018074334A2 (pt) uso de células tronco mesenquimais e partes das mesmas
SV2017005367A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
BR112015018104A2 (pt) polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
BR112017015310A2 (pt) uso de pgr4 como um agente anti-inflamatório
EA201691582A1 (ru) Новые фармацевтические препараты
CR20160561A (es) Variantes del anticuerpo anti-factor d y sus usos
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
BR112017008344A2 (pt) extrato, uso de um extrato, e, composição cosmética ou dermofarmacêutica.
BR112014019233A2 (pt) emplastros medicinais para criar ou manter uma área de tecido humano livre de contaminantes
BR112016030577A2 (pt) vacinas contra o vírus da gripe e usos das mesmas
BR102014006335B8 (pt) Método para produzir uma população isolada de células-tronco de polpa dentária imaturas (idpscs) e uso
ECSP18060875A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
BR112021006280A2 (pt) terapias imunoablativas
BR112018074437A2 (pt) cepa de bacillus licheniformis com atividade probiótica
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
CL2020000812A1 (es) Semaglutida en la terapia médica.
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
BR112015010223A2 (pt) compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
EA202090270A1 (ru) Новые замещенные производные ксантина
BR112018016715A2 (pt) ?formulações de oritavancina?

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements